The Current Ratio as of November 2024 (TTM) for Molecular Partners AG (MOLN) is 14.33

According to Molecular Partners AG’s latest financial reports and current stock price. The company's current Current Ratio is 14.33. This represents a change of 0.68% compared to the average of 14.23 of the last 4 quarters.

Molecular Partners AG (MOLN) Historical Current Ratio (quarterly & annually)

How has MOLN Current Ratio performed in the past?

The mean historical Current Ratio of Molecular Partners AG over the last ten years is 8.08. The current 14.33 Current Ratio has changed 17.63% with respect to the historical average. Over the past ten years (40 quarters), MOLN's Current Ratio was at its highest in in the March 2016 quarter at 54.65. The Current Ratio was at its lowest in in the June 2020 quarter at 2.32.

Molecular Partners AG (MOLN) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Molecular Partners AG Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Molecular Partners AG (MOLN) Average Current Ratio

How has MOLN Current Ratio performed in the past?

The current Current Ratio of Molecular Partners AG (MOLN) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Molecular Partners AG (MOLN) Current Ratio vs. Peers

How is MOLN’s Current Ratio compared to its peers?

Molecular Partners AG’s Current Ratio is greater than Mineralys Therapeutics, Inc. (8.55), greater than AN2 Therapeutics, Inc. (9.75), less than Pharvaris N.V. (19.08), greater than PepGen Inc. (8.47), less than MediciNova, Inc. (16.66), greater than Anebulo Pharmaceuticals, Inc. (3.45), greater than Champions Oncology, Inc. (0.69), less than Cyteir Therapeutics, Inc. (21.89), greater than Rezolute, Inc. (13.79), greater than HCW Biologics Inc. (0.07), less than Eliem Therapeutics, Inc. (60.41), greater than PMV Pharmaceuticals, Inc. (13.98), less than Edgewise Therapeutics, Inc. (26.35), greater than Rallybio Corporation (9.55), greater than Opthea Limited (2.94), greater than Monte Rosa Therapeutics, Inc. (6.03), greater than Entrada Therapeutics, Inc. (6.59), greater than Vigil Neuroscience, Inc. (3.72),

Build a custom stock screener for Molecular Partners AG (MOLN) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Molecular Partners AG using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Molecular Partners AG (MOLN) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Molecular Partners AG or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.